Medicare drug denials get a fast-track appeal—but at what cost?

What it does

This bill creates a formal review process allowing drugmakers and others to challenge Medicare's decisions to deny or limit coverage of FDA-approved drugs. When a drug is approved by the FDA but Medicare refuses to cover it nationally, the bill requires Medicare to review the decision within 90 days, hold a 30-day public comment period, and issue a final decision within 120 days—with Medicare required to explain its reasoning and release clinical evidence if it reverses course. The bill also prevents Medicare from applying old coverage denials to newly approved drugs and blocks Medicare Part D plans from using outdated national coverage denials when deciding whether to cover a drug.

Why we flagged it

The bill's core function is to establish a formal, time-bound review and appeal process for Medicare national coverage determinations (NCDs) that deny or limit coverage of FDA-approved drugs. It is not a direct subsidy or carve-out, but a procedural mechanism that shifts decision-making pressure toward coverage approval.

What the text implies

• The 90-120 day review timeline may be too compressed for rigorous clinical evidence review, potentially forcing Medicare to approve drugs on limited data to meet the deadline.
• By prohibiting Medicare from applying prior NCDs to newly approved drugs, the bill may create a loophole where a drug approved for a narrow indication can be used off-label without Medicare coverage review.
• The requirement to 'make available to the public the clinical evidence' when reversing a decision creates asymmetric transparency—Medicare must disclose evidence supporting reversal but the bill does not require disclosure of evidence supporting denial.
• Part D plans are barred from using 'specified national coverage determinations' (old denials), but the bill does not clarify whether plans can still apply their own formulary restrictions or cost-sharing, potentially shifting cost burden to beneficiaries.
• The bill does not define who may request a review—it is unclear whether only manufacturers can petition, or whether patient groups, providers, and others can also trigger the 90-day clock.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates transparency and a formal appeal process for coverage decisions, which could help patients access newly approved treatments faster. However, the mechanism may pressure Medicare to approve drugs with limited evidence of benefit, potentially raising costs for beneficiaries through higher premiums and cost-sharing, and the 90-120 day timeline is aggressive for rigorous clinical review.

Who stands to gain

• pharmaceutical manufacturers
• biopharmaceutical companies
• medical device manufacturers

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Medicare, FDA, Medicare Coverage Advisory Committee, Part D prescription drug plans, MA-PD plans, Social Security Act Section 1862, Social Security Act Section 1860D-2

Where it stands

1 cosponsor: 1 Republicans.

• Jun 24, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 24, 2026 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $1,930,000 in lobbying spend. A filing names 22 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Nanette Barragán, the sponsor, reported $698,300 in PAC receipts in the 2026 cycle.

• Alzheimer's Association — $1,800,000 on 1 filing
• Usagainstalzheimers Action — $130,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.